Absci(ABSI) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 – Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2024. "During the first quarter, we made significant strides in advancing both ...